Related Experiment Videos
Beta-2 adrenoceptor genotype and progress in term and late preterm active labor
Russell S Miller1, Richard M Smiley, Danette Daniel
1Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Columbia University Medical Center, New York, NY 10032, USA. rsm20@columbia.edu
American Journal of Obstetrics and Gynecology
|May 24, 2011
Summary
The beta-2 adrenoceptor (β2AR) Arg/Arg16 genotype is linked to slower cervical dilatation during active labor. This finding impacts understanding of labor progression and genetic influences.
Area of Science:
- Obstetrics and Gynecology
- Pharmacogenetics
- Reproductive Medicine
Background:
- The beta-2 adrenoceptor (β2AR) plays a role in smooth muscle function.
- Genetic variations in β2AR may influence physiological processes, including labor progression.
- Cervical dilatation rate is a key indicator of labor progress.
Purpose of the Study:
- To investigate the association between beta-2 adrenoceptor (β2AR) genotype at residue 16 and the rate of cervical dilatation.
- To determine if specific β2AR genotypes affect labor progression in term and late preterm active labor.
Main Methods:
- Retrospective analysis of 401 women undergoing vaginal delivery at ≥34 weeks gestational age.
- DNA extraction for β2AR genotyping from venous blood samples.
- Calculation of cervical dilatation rate using digital cervical examination data and linear regression.
Main Results:
- The overall rate of active labor cervical dilatation was 0.76±0.01 cm/h.
- Women with the homozygous Arg/Arg16 β2AR genotype exhibited a significantly slower rate of cervical dilatation (0.64±0.03 cm/h) compared to other genotypes (0.8±0.02 cm/h, P<.001).
Conclusions:
- The homozygous β2AR genotype encoding for Arg/Arg16 is associated with slower cervical dilatation in active labor.
- This genetic variation may be a factor influencing the duration and progress of labor.
Related Concept Videos
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:26Adrenergic Receptors: β Subtype
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
01:27Adrenergic Receptors (Adrenoceptors): Classification
Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors, which are found on postsynaptic...
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors, which are found on postsynaptic...
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...